The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Explore decentralized clinical trials (DCT) and the oversight role of the sponsor. During COVID-19, many trials have been modified and changed to account for the inability to interact with subjects in person and many organizations have moved to a decentralized architecture. Session participants will: understand the regulations pertaining to decentralized clinical trials, learn the perceived benefits and challenges of a DCT, and discuss remote monitoring of DCTs.
Learning Objectives:
Understand the regulations pertaining to decentralized clinical trials.
Learn the perceived benefits and challenges of a DCT.
Discuss remote monitoring of DCTs.
Speaker(s):
Eric
Pittman,
MBA,
Program Division Director,
U.S. Food and Drug Administration
Credits
1.00
- ACRP Credits
You must be logged in and own this session in order to
post comments.
Regina Ingram
4/6/21 6:11 pm
Excellent